Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
DOXORUBICIN is recognized as one of the most active drugs for breast cancer, but its clinical
utility is limited because of a cumulative dose-dependent cardiac myopathy that can lead to
potentially fatal congestive heart failure. Caelyx (pegylated liposomal doxorubicin) was
designed to reduce the cardiotoxicity of doxorubicin while preserving its antitumor efficacy